Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

NCT03447808 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL: Daratumumab
DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

Jennifer Woyach